Chemomab Therapeutics (NASDAQ:CMMB) Shares Up 9.2% – Time to Buy?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s stock price was up 9.2% during trading on Thursday. The stock traded as high as $1.40 and last traded at $1.30. Approximately 195,376 shares were traded during mid-day trading, an increase of 25% from the average session volume of 156,096 shares. The stock had previously closed at $1.19.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CMMB shares. Wall Street Zen raised Chemomab Therapeutics to a “hold” rating in a report on Saturday. Weiss Ratings raised Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Chemomab Therapeutics Price Performance

The company’s 50-day moving average price is $2.14 and its two-hundred day moving average price is $1.86. The company has a market capitalization of $10.37 million, a price-to-earnings ratio of -0.67 and a beta of 0.74.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings results on Thursday, August 20th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12).

Institutional Trading of Chemomab Therapeutics

An institutional investor recently raised its stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC grew its stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 19.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 61,710 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Kestra Private Wealth Services LLC owned 0.86% of Chemomab Therapeutics worth $97,000 at the end of the most recent reporting period. 46.05% of the stock is currently owned by institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is based on the role of CCL24, a chemokine believed to contribute to inflammation, tissue remodeling and fibrosis across multiple organs.

Chemomab’s lead product candidate is CM-101, an investigational monoclonal antibody designed to block CCL24 activity. The company is evaluating CM-101 in diseases including systemic sclerosis, also known as scleroderma, and primary sclerosing cholangitis, a chronic liver disease.